Loading
A phase 3 trial of Epcoritamab, Rituximab, Lenalidomide in follicular lymphoma, run by Genmab, active and no longer recruiting.
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma is a phase 3 interventional study registered as NCT05409066 by Genmab, with 549 participants enrolled, started 2022-09-20 and due to reach its primary completion in 2029-12. Interventions recorded: Epcoritamab, Rituximab, Lenalidomide. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.
Shares Epcoritamab, Genmab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Epcoritamab, Genmab, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, T-cell engagers (bispecific).
Shares Epcoritamab, Genmab, T-cell engagers (bispecific), Follicular lymphoma.
Shares Epcoritamab, Genmab, Lenalidomide, Rituximab.
Shares Epcoritamab, Genmab, Rituximab, T-cell engagers (bispecific).